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Abstract
Background: Roux-en-Ygastric bypass (RYGB) and sleeve gastrectomy (SG) rank among the most frequently applied
bariatric procedures worldwide due to their positive risk/benefit correlation. A systematic review revealed a similar
excess weight loss (EWL) 2 years postoperatively between SG and RYGB. However, there is a lack of randomized
controlled multi-centre trials comparing SG and RYGB, not only concerning EWL, but also in terms of remission of
obesity-related co-morbidities, gastroesophageal reflux disease (GERD) and quality of life (QoL) in the mid- and
long-term.
Methods: The BariSurg trial was designed as a multi-centre, randomized controlled patient and observer blind trial.
The trial protocol was approved by the corresponding ethics committees of the centres. To demonstrate EWL
non-inferiority of SG compared to RYGB, power calculation was performed according to a non-inferiority study
design. Morbidity, mortality, remission of obesity-related co-morbidities, GERD course and QoL are major secondary
endpoints. 248 patients between 18 and 70 years, with a body mass index (BMI) between 35–60 kg/m2 and
indication for bariatric surgery according to the most recent German S3-guidelines will be randomized. The primary
and secondary endpoints will be assessed prior to surgery and afterwards at discharge and at the time points 3–6,
12, 24, 36, 48 and 60 months postoperatively.
Discussion: With its five year follow-up, the BariSurg-trial will provide further evidence based data concerning the
impact of SG and RYGB on EWL, remission of obesity-related co-morbidities, the course of GERD and QoL.
Trial registration: The trial protocol has been registered in the German Clinical Trials Register DRKS00004766.
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Background
Rationale of the trial
The effect of bariatric surgery on obesity and related co-
morbidities such as type 2 diabetes mellitus (T2DM) or
hypertension is no longer doubted [1–3]. Reliable data
showing improved overall patient survival and a reduced
cancer incidence, especially in females, following bariat-
ric surgery are available [4]. Additionally, bariatric sur-
gery can now be performed safely and with acceptable
morbidity and mortality [5, 6]. The procedures per-
formed in the field of bariatric surgery are still evolving
and include rather simple procedures such as gastric
banding and more advanced techniques, such as bilio-
pancreatic diversion or ileal transposition. Looking from
a more general point of view, Roux-en-Y gastric bypass
(RYGB) and sleeve gastrectomy (SG) are the most com-
monly performed procedures worldwide and in
Germany, a finding that is likely due to their positive
risk/benefit correlation [6]. However, RYGB is still con-
sidered superior to SG [7, 8]. This belief, however, is
mostly based on historical considerations, as RYGB was
one of the first bariatric procedures ever performed [9].
Because of recent evidence including systematic reviews
and randomized controlled trials, SG has become more
and more accepted as a stand-alone bariatric surgery
procedure [9–17]. The systematic review data revealed,
among other things, that excess weight loss (EWL) after
SG was not significantly different from EWL following
RYGB, 24 months after surgery [13]. This finding is con-
sistent with that of Peterli et al., who also observed no
significant differences in 12 month post-op EWL be-
tween SG and RYGB [9]. Another randomized con-
trolled trial (RCT) from Finland, comparing SG and
RYGB, revealed a significantly reduced operative time
and complication rates in favour of the SG group [12].
As a result, the German statistic on obesity surgery for
2011 revealed for the first time, that more SG resections
than RYBGs were performed [13, 18, 19]. Nevertheless,
SG is still regarded with some scepticism due to the lack
of valid long-term results and RCTs. Major criticism in-
cludes not only the effect of SG on EWL, but also on
the course of obesity-related co-morbidities, on gastro-
esophageal reflux disease (GERD), and on quality of life
(QoL) [20–23]. Furthermore, it seems that SG is corre-
lated with rather specific complications such as fistulas
and/or stenosis. The incidence of these complications is
reported with the range 0 % to 17.5 % [19]. However, SG
has a rather fast learning curve and can be performed
within a short operative time. In addition, SG is consid-
ered less technically challenging than RYGB, due to the
lack of anastomosis. Based on these unresolved contro-
versies, further RCTs comparing SG and RYGB are ur-
gently needed. The available RCT’s show that the clinical
efficacy regarding EWL and T2DM remission between
both procedures are comparable [14, 15, 24]. This goes
along with similar morbidity rates even though it seems
that the morbidity rate of RYGB in these RCTs is higher
[12, 15].
Objective
The primary endpoint of the BariSurg RCT, to compare
EWL rates 2 years after SG and RYGB, was chosen
based upon systematic review findings [13]. BariSurg will
be a multi-centre, randomized controlled, patient and
observer blind trial. Major secondary endpoints will be
morbidity, mortality, re-operation rate, remission of
obesity-related co-morbidities, the occurrence and
course of GERD, QoL, the course of the dumping syn-
drome, and the EWL rate 60 months after surgery.
Trial locations
The BariSurg RCT will be conducted at seven bariatric cen-
tres: the University of Heidelberg, Städtisches Klinikum
Karlsruhe, Agaplesion Bethesda Krankenhaus Stuttgart,
Schwarzwald-BaarKlinikum (Villingen-Schwenningen),
Caritas-Krankenhaus St. Josef (Regensburg), Johanniter
Krankenhaus (Bonn) and Sana Klinikum Offenbach
GmbH (Offenbach).
Methods/Design
Trial design
The BariSurg trial is a multi-centre, randomized con-
trolled, patient and observer blind trial.
Sample size
A total of 248 patients will be randomized, with 124 pa-
tients assigned to each treatment arm. A dropout rate of
approximately 20 % is considered realistic and has been
accounted for the total number of randomized patients.
Patient selection criteria
Patients between 18 and 70 years old with a BMI be-
tween 35 and 60 kg/m2 with indication for bariatric sur-
gery according to the most recent German S3 guidelines
will be eligible. Patients with a BMI of 35–40 kg/m2
need to have at least one obesity-related co-morbidities
such as T2DM or hypertension (see Table 1).
Recruitment and timelines
Patients will be recruited by the above mentioned seven
participating centres. The recruitment period is esti-
mated at 18 months. The time from enrollment of the
first patient to study completion of the last, will be ap-
proximately 78 months, and the proposed duration of
the entire trial is 90 months.
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Randomization
Patients fulfilling all inclusion without meeting any
exclusion criteria and after receiving their informed
consent, randomization will be performed intraoper-
atively via an internet-based randomization tool
(http://www.randomizer.at). Randomization is per-
formed by block randomization and will be stratified
for each centre until the enrolment goal of 248 pa-
tients has been reached.
Interventions
Patients will be asked to complete standard preoperative
diagnostics including esophagogastroduodenoscopy (EGD),
endocrine assessment and psychosomatics, and will also fill
out four questionnaires (Short-Form-36 Health Survey
(SF-36) [25], Gastrointestinal Quality of Life Index (GIQLI)
[26], the Dumping questionnaire (Sigstad score) and
Gastrointestinal Symptom Rating Score (GSRS) [27, 28]).
Two weeks before surgery, patients will be asked to reduce
their weight by following a low calorie liquid diet [29]. Pre-
operatively, a single-shot antibiotic prophylaxis will be
given. For the surgical procedure, the patient will be placed
in the supine position 45° (reverse Trendelenburg).
Roux-en-Y-gastric bypass
After the gastroesophageal junction is identified, the stom-
ach is transsected with a linear stapler 6 cm below the
junction. A pouch with a 4–6 cm height and 14–16 mm
width is created using a 42 French tube. A 70 cm biliopan-
creatic limb is defined and an end-to-side gastroenterost-
omy will be performed using either a 30 mm linear or
25 mm circular stapling technique. The common channel
(side-to-side jejunojejunostomy) will be stapled after an-
other 150 cm antecolic limb. To identify a leak of the
proximal anastomosis methylene blue is applied through a
nasogastric tube [30]. All patients will be discharged with
the recommendation of oral intake of multivitamin tablets
twice daily. During the follow up examination vitamin
levels will be assessed regularly. In case of vitamin defi-
ciency substitution of vitamins will be performed.
Sleeve gastrectomy
The gastroepiploic vessels are divided 6 cm prepyloric
along the great curvature, until the angle of His and the
left crus of the diaphragm are visible. Along with a 42
French bougie, the stomach is then resected using linear
stapler devices. At the angle of His the stapler line is su-
tured. The sleeve is checked for leakage using methylene
blue. All patients will be discharged with the recommen-
dation of oral intake of multivitamin tablets twice daily.
Study visits
Study documentation and visits of patients will be per-
formed by both surgeons and study nurses. Since the
trial is designed as observer and patient blind RCT, in-
formation about the surgical procedure will not be re-
ported during the follow-up examinations. There will be
9 study visits during the BariSurg RCT (see Fig. 1). Dur-
ing the first postoperative year, study visits will be per-
formed at discharge, 3–6 months and 12 months
postoperatively. Then visits will be performed annually.
Every postoperative study visit includes data collection
of weight, morbidity, mortality, course of obesity-related
co-morbidities (including laboratory parameters and
current medication), analysis of nutritional supplementa-
tion, occurrence of GERD and analysis of dumping syn-
drome using the Sigstad score. In addition to the above
mentioned information, extended study visits will yearly
assess general laboratory parameters, EGD results and
the questionnaires (SF-36, GIQLI, GSRS, see Fig. 1).
Risk-benefit ratio
SG is associated with a morbidity rate between 0–17.5 %
and a mortality rate between 0–1.2 % [13]. The most fre-
quently occurring postoperative complications are insuffi-
ciencies/fistulas at the staple line, leakage, stenosis of the
sleeve and dilatation of the sleeve [5]. RYGB has a morbid-
ity rate of 2-10 % and a mortality of 0.5-0.8 % [7, 12, 15].
Frequently observed complications include anastomotic in-
sufficiency, especially with regard to the gastrojejunostomy,
and dumping syndrome. Dumping syndrome is observed
in 42 % after RYGB and up to 29 % after SG [31–33].
Therefore patients will be assessed for dumping syndrome.
If the diagnosis dumping syndrome is confirmed patients
will get the optimal treatment for dumping syndrome [28].
For both bariatric procedures, nutritional supplementation
might be necessary for the remainder of the patient’s life.
Outcome
The summary of the primary and the secondary endpoints
depicts different points of view concerning the efficacy
and safety of bariatric procedures. In doing so, medical is-
sues as well as patient assessment can be analyzed.
Primary endpoint
The primary endpoint is defined as EWL at 24 months
after surgery (RYGB or SG). Power calculation was made
according to the systematic review of Fischer et al. [13].
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
BMI 40-60 kg/m2 Lack of informed
consent
BMI 35–40 kg/m2 with at least
one obesity-related co-morbidity
Expected lack of
compliance
Age 18–70 years Previous bariatric
surgery
Pregnancy
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Fig. 1 Flow chart of BariSurg trial, showing the timeline and the course for trial participants. Abbreviations: BMI: body mass index, T2DM: type 2
diabetes mellitus, EWL: excess weight loss, EGD: esophagogastroduodenoscopy, SF-36: Short-Form-36 Health Survey, GIQLI: gastrointestinal quality
of life index, GSRS: gastrointestinal symptom rate score, EWL: excess weight loss, GERD: gastroesphageal reflux disease
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Secondary endpoints
Long-term EWL at 60 months after surgery, morbidity,
mortality, course of obesity-related co-morbidities
(T2DM, hypertension, joint pain, sleep apnoea, dyslipid-
emia), vitamin status, incidence and/or course of GERD
and QoL (as defined by the SF 36) and dumping syndrome
(as defined by the Sigstad score) will form the secondary
endpoints. The course of obesity-related co-morbidities is
assessed by laboratory examinations and current medica-
tion use. T2DM remission will be measured by HbA1c,
fasting glucose and medication use. Hypertension will be
monitored by medication and blood pressure measure-
ments. The course of joint pain and dyslipidemia are
assessed by pain and respectively lipid metabolism medi-
cation. The course of sleep apnoea is analysed by patients’
application of CPAP-mask. Nutritional substitution will be
assessed using a questionnaire which was developed in the
bariatric centre of the University of Heidelberg. GERD in-
cidence and course of GERD will be assessed with EGD
and by using GSRS and GIQLI as standardized question-
naires. To evaluate QoL, the validated SF-36 questionnaire
will be used. The Dumping score will be evaluated by
using the validated Sigstad score. Secondary endpoints will
be evaluated preoperatively, at discharge, 3-6, 12, 24, 36,
48 and 60 months postoperatively. Questionnaires will be
filled out 12, 24 and 60 months after surgery. The EGD
will be performed 12 and 60 months postoperatively.
Data management
Trial-relevant data will be documented in the case re-
port form (CRF). The original CRFs will remain at the
investigating centre and copies will be sent to the pri-
mary investigating centre, i.e. University Heidelberg.
Data extraction and analysis will be made by the con-
tract research organization, R&P Ryschlick and Partner
GmBH (Burscheid, Germany). Data will be analyzed for
completeness, validity and plausibility. The investigator
will be consulted in case of uncertainty of the data.
Safety evaluation and reporting of adverse events
Patients will receive regular medical treatment, in-
cluding any necessary emergency treatment, through-
out the duration of the trial. Serious adverse events
(SAE) are defined as the need for re-operation, pro-
longed hospitalization, life-threatening situations, re-
admission for any reason, and death. The principal
investigator must be informed about all occurring
SAEs within 24 hours of knowledge of the event. All
SAEs must be reported to the principle investigator.
Unblinding
Blinding of patients has been done many times even in
surgery [34–36]. Besides randomization, blinding of pa-
tients (and observers) reduces bias. Subsequently, internal
and external validity will be increased. The fact that this
study will be a patient and observer blinded study made a
thoroughly ethical and clinical evaluation necessary. Based
on the given evidence there is reliable data available that
both procedures are similar in their clinical efficacy
regarding excess weight loss, diabetes remission and com-
plication rates [13–15]. Taking aside historical consider-
ations and looking only at the RCT regarding RYGB and
SG one can truly suggest to patients that both procedures
are equally effective and safe.
During the BariSurg trial, all patients get extensive oral
and written information about both procedures with all
relevant pros and cons. Patients are informed that they
will not know which procedure will be performed.
Randomization will be performed intraoperatively after
confirming that both procedures can be performed
safely. All relevant documents including operation report
and discharge letter state that the patient was enrolled
in a randomized controlled patient and observer blind
clinical trial comparing RYGB and SG and that the pa-
tient does not know about the procedure. These docu-
ments also include an emergency number which
patients or physicians can call any time (24 hours,
365 days service) in case unblinding is necessary. Thus,
blinding patients during the BariSurg trial is reasonable
both from a clinical point of view as well as from ethical
considerations.
Statistical methods
Sample size
According to a systematic review by Fischer et al. the
mean EWL two years after SG and RYGB was 56.1 %
and 68.3 % respectively, with a common standard devi-
ation of 22.5 % [13]. Based on these results, the null hy-
pothesis is that there exits inferiority of SG compared to
RYGB in EWL 24 months after surgery. Based on the as-
sumption that a difference in EWL of 10 % or more is
clinically relevant, the margin to consider EWL as simi-
lar is set to 9 %. The power calculation for a non-
inferiority trial with a one-sided t-test (alpha = 0.025 %
and beta = 20 %) and a standard deviation of 22.5 % re-
vealed that 99 patients per intervention group need to
be randomized. Since a high dropout rate of 20 % is ex-
pected, a further 25 patients per intervention group
should be randomized. Hence a total of 124 patients for
each group will be recruited (overall 248 patients).
Analysis of primary endpoint
The primary endpoint is percent of EWL 24 months after
surgery. To formalize the statistical approach, the follow-
ing notations will be used: μRYGB/μSG, population mean
of primary endpoint in RYGB/SG group. The following
one-sided non-inferiority test problem is defined as
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H0: μRYGB - μSG > = delta vs.
H1: μRYGB - μSG < delta
(For definition and specification of delta, see sample
size calculation). This hypothesis will be tested using a
one-sided t-test applied to each protocol population (see
below). A low number of missing values for the primary
endpoint is expected. If any values are missing, they will
be replaced by methods of multiple imputation.
Secondary analyses
Concerning secondary endpoints, exploratory data ana-
lysis will be performed and appropriate summary mea-
sures for the empirical distribution, as well as descriptive
two-sided p-values, will be calculated. Homogeneity of
the treatment groups will be described by comparing the
baseline values. Each patient’s allocation to the different
analysis populations [full analysis set (FAS) according to
the intention-to-treat (ITT) principle, per protocol (PP)
analysis set, safety analysis set] will be defined prior to
analysis and documented in the analysis plan prior to
database closure. During the data review, deviations
from the protocol will be assessed as 'minor' or 'major'.
Major deviations from the protocol will lead to the
patient's exclusion from the PP analysis set. In addition
to the evaluation of PP, an ITT analysis will be per-
formed as a sensitivity analysis.
Safety measures
Safety analysis includes frequency of SAEs and complica-
tions. Homogeneity of the study arms will be described
by comparing demographic data with baseline values.
Withdrawals and stopping guidelines
Patient withdrawal from the trial is possible at any time
and without explanation. The trial will be ended in cases
of insufficient patient recruitment and a high rate of
SAEs due to SG or RYGB.
Data safety monitoring board
Reports of SAEs will be collected by an independent
data and safety monitoring board (DSMB). Furthermore,
the DSMB will inform the trial management about rele-
vant imbalances between the two groups.
Trial organization and administration
Ethical considerations
SG and RYGB are frequently performed, standard tech-
niques in bariatric surgery. The overall complication rate in
SG and in RYGB described by Birkmeyer et al. is 5.9 % and
10.3 % respectively. A mortality of 0 % in SG and 0.3-0.9 %
in RYGB was observed [12, 15, 37]. All participating centres
perform both techniques frequently. In this manner mor-
bidity and mortality rate can be expected like above
mentioned. Furthermore, all participating centres re-
ceived positive approvals of the according ethic com-
mittees (i.e. the University of Heidelberg from the
Heidelberg ethics committee (S500/2012), Johanniter
Hospital (Bonn) (2015179/2014), Städtisches Klinikum
Karlsruhe, Schwarzwald-Baar-Klinikum (Villingen-
Schwennigen), Agaplesion Bethesda Krankenhaus
Stuttgart from the ethics committee of the State Board
of Physicians of Baden-Württemberg which is respon-
sible for the mentioned hospitals (B-F-2014-059)). The
Caritas-Krankenhaus St. Josef (Regensburg) requested for-
mal information of the ethics committee of the Bavarian
State Board of Physicians to be legally considered a posi-
tive ethic vote.)
Good clinical practice
The BariSurg trial will be conducted according to national
and international trial standards (ICH-GCP, Declaration
of Helsinki 2008).
Registration
This trial is registered in the German Clinical Trials
Register (DRKS00004766).
Discussion
The positive effects of bariatric surgery on weight loss and
obesity-related co-morbidities are no longer doubted. In
addition, these procedures can also be performed safely
with low mortality and morbidity [5, 12, 38]. The range of
available bariatric procedures is tremendous [7, 17, 39–45].
Almost every year, a “new” procedure is focussed upon
within the scientific community [18, 19]. However, there
are only few RCTs comparing the two most commonly per-
formed bariatric procedures, i.e. RYGB and SG with regard
to actual weight loss and/or improvement of obesity-
related co-morbidities in the mid- and long-term [12, 15].
It is therefore impossible to advocate any particular, bariat-
ric surgical method, because one still does not know which
patient benefits most from which procedure. A systematic
review revealed that the EWL after 24 months is not statis-
tically different between RYGB and SG [41]. In addition,
the same publication demonstrated the poor data quality
among publications dealing with SG. The urgent questions
concerning comparisons between SG and the current gold
standard of RYGB with respect to long-term EWL, course
of obesity-related co-morbidities, course of GERD and
QoL, are still not answered. In the last 2 years, however,
a small number of RCTs were started with the goal
of examining some of these issues [12, 14, 15, 17,
39]. To our knowledge, the BariSurg trial will be the
first multi-centre, randomized controlled patient and
observer blind clinical trial with a sufficient sample
size analyzing hard clinical endpoints such as mid-
and long-term EWL, morbidity and mortality. In
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addition BariSurg will also answer some of the ur-
gent questions associated with SG, such as course of
obesity-related co-morbidities, dumping syndrome
and GERD. Thus, BariSurg will contribute to class
1B evidence, which enable future class 1A evidence
in form of meta-analyses. The remission of obesity-
related co-morbidities, such as T2DM, following bar-
iatric procedures is already known [1–3, 40]. In par-
ticular, the RYGB has been considered as a potential
therapy for T2DM, even in patients with a BMI of
less than 35 kg/m2 [41, 42]. However, SG also has a
significant impact on T2DM remission [24, 43, 46].
Prior RCTs have suggested similar outcomes after
RYGB and SG with regard to glucose metabolism
[15, 44, 47]. The incidence of GERD seems to be
more frequent after SG whereas RYGB is considered
a therapeutic option in patients with GERD [15, 45,
48]. Nevertheless, the course of GERD after SG is
controversial and definite evidence supporting either
side does not exist [23, 49, 50]. The current discus-
sion among bariatric surgeons is almost unidirec-
tional and focused on “hard” clinical facts such as
weight loss, T2DM remission, and the course of
other obesity-related co-morbidities. “Soft” clinical
facts such as QoL have gained importance. At the
present, there is few literature about patients’ expect-
ation concerning surgical intervention. Data from the
Michigan Bariatric Surgery Collaborative on a total
of 8.847 patients showed an increased qoL after SG
and RYGB [51]. However long-term results of QoL
after RYGB and SG are not available. The combined
evaluation within this trial of the primary endpoint
of EWL after 24 months plus the course of EWL,
obesity-related co-morbidities, GERD, morbidity and
mortality over 5 years, will lead to further insights of
the pros and cons of both procedures. Additionally,
the setting of this multi-centre, randomized trial en-
ables a maximum reduction of bias and increases in-
ternal and external validity [52].
Trial status
Recruitment started in November 2013.
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